000			03315cam a2200421Ii 4500
001			96321
003			ES-MaUEC
005			20230102112749.0
006			m o d
007			cr cnu|||unuuu
008			170712s2017 sz ob 001 0 eng d
020			_a3319239090
020			_a3319239104 _q(electronic bk.)
020			_a9783319239095
020			_a9783319239101 _q(electronic bk.)
020			_z9783319239095
040			_aN$T _cN$T _dEBLCP _dN$T _dGW5XE _dYDX _dOCLCO _dOCLCF _dNJR _dUAB _dOCLCO _dAZU _dESU _dUPM _dVT2 _dIOG _dCOO _dGZM _dMERER _dOCLCQ _dOCLCO _dJG0 _dOCLCO _dOCLCA _dES-MaUEC _bspa
050		4	_aRC271.I45 _b2017 EB
245	0	0	_aCancer vaccines _cNatalia Savelyeva, Christian Ottensmeier, editors.
264		1	_aCham, Switzerland _bSpringer _c2017.
300			_a1 recurso en línea
336			_aTexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
347			_atext file _bPDF
490	0		_aCurrent topics in microbiology and immunology _x2196-9965 _vvolume 405
500			_aSpringerLink _bSpringer Biomedical and Life Sciences eBooks 2017 English+International
504			_aIncluye referencias bibliográficas e índice
505	0		_aNew Approaches in Immunotherapy for the treatment of Lung Cancer -- Novel approaches for vaccination against HPV-induced cancers -- Tapping the potential of DNA Delivery with Electroporation for Cancer Immunotherapy -- Targeted immunotherapy designed to treat Muc1-expressing solid tumour -- Chimeric DNA vaccines: an effective way to overcome immune tolerance -- Linked CD4 T-cell help: broadening immune attack against cancer by vaccination -- mRNA cancer vaccines - Messages that prevail -- The Use of Anti-CD40 mAb in Cancer.
506			_aAccess restricted to subscribing institutions.
520	3		_aThis volume focuses on the laboratory and clinical experience with targeting viral onco-antigens, while also reviewing the approaches to targeting self-cancer antigens in cancers of non-viral origin, where self-tolerance has been a challenge. It emphasizes the importance of selecting the right vaccine platform to induce a successful immune response against cancer antigens. In addition, the volume discusses the advances made with genetic vaccines, including recent advances with DNA vaccines and the rapid transition of mRNA vaccines from the laboratory to bedside. The new avenues opening up for cancer immunotherapy underline the importance of combinational approaches using cancer vaccines with costimulatory antibodies, which may dramatically improve cancer treatment. This book is intended for all translational researchers and clinicians who aspire to develop novel vaccination approaches for cancer patients with unmet clinical needs.
650		7	_aCancer _xVaccination. _2fast _0(OCoLC)fst00845559 _9139308 _0comprobar BNE19900970859
700	1		_aOttensmeier, Christian, _eeditor literario
700	1		_aSavelyeva, Natalia _c(Lecturer in Cancer Immunology), _eeditor literario
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=http://link.springer.com/10.1007/978-3-319-23910-1 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
988			_aEBOOK, asignarmaterias, EBSPRINGER_2017D
998			_b02/2018 _dz _e- _zSI
999			_c96321 _d96321 _x1